Iconovo AB (publ)

Stockholm Stock Exchange ICO.ST

Iconovo AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -2.26 M

Iconovo AB (publ) Capital Expenditure is USD -2.26 M for the year ending December 31, 2023, a 35.92% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Iconovo AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -3.53 M, a -23.78% change year over year.
Iconovo AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -2.85 M, a -87.03% change year over year.
Iconovo AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -1.52 M, a -78.86% change year over year.
Iconovo AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -852.23 K, a -46.62% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: ICO.ST

Iconovo AB (publ)

CEO	Mr. Johan Waborg
IPO Date	April 6, 2018
Location	Sweden
Headquarters	Medicon Village
Employees	28
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.

Key trends

Past 5 years